Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which…

Read MoreAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Marinus…

Read MoreMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement…

Read MoreHDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused…

Read MoreU.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

TigerConnect® Named a Leader in the 2023 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration

TigerConnect, healthcare’s most trusted clinical collaboration platform, today announced it has been named a Leader in the 2023 Gartner Magic Quadrant for Clinical Communication and Collaboration (CC&C). The evaluation was based on inclusion criteria that included platforms’ competitive product offerings…

Read MoreTigerConnect® Named a Leader in the 2023 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration